/filters:format(webp)/production/7612664/large-1738772383.png?1738772383)
Tdorsey1776
$VRDN RBC Capital raised the firm's price target on Viridian Therapeutics to $38 from $36 and keeps an Outperform rating on the shares. The firm has spoken to 6 TED key opinion leaders who collectively see about 2,000 TED patients about Lumvoa's launch, noting that it is pleasantly surprised to hear that 3/6 of the physicians have written at least 1 or more Rx, and 2/6 have reported infusing at least 1 patient so far, suggesting some payer access has gone smoothly, the analyst tells investors in a research note. While it is still early days for Lumvoa, the evidence of early adopters is encouraging suggesting physicians are eager to gain experience with Lumvoa and see how it compares to Tepezza in terms of efficacy/safety, the firm added
/filters:format(webp)/production/11019452/large-1781202037.png?1781202037)
/filters:format(webp)/images/default_avatar_4_large.png){kind=avatar}
